middle.news
Invion Advances Photosoft Trials, Secures $2M to Expand Cancer Pipeline
4:15am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Invion Advances Photosoft Trials, Secures $2M to Expand Cancer Pipeline
4:15am on Monday 2nd of June, 2025 AEST
Key Points
Dosed 5 patients in Phase I/II skin cancer trial across two Queensland sites
Expanded Hanlim Pharm collaboration to include oesophageal cancer indication
Raised $2 million via a two-tranche share placement to fund clinical programs
Photosoft technology featured at Stanford Lung Cancer Summit
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Invion (ASX:IVX)
OPEN ARTICLE